Shire PLC (NASDAQ:SHPG)‘s stock had its “buy” rating reissued by stock analysts at Goldman Sachs Group Inc. in a research note issued on Sunday.
Several other equities analysts have also issued reports on SHPG. Zacks Investment Research upgraded Shire PLC from a “hold” rating to a “buy” rating and set a $192.00 target price for the company in a research report on Wednesday, June 29th. Jefferies Group restated a “buy” rating on shares of Shire PLC in a research report on Friday, July 1st. Shore Capital restated a “buy” rating on shares of Shire PLC in a research report on Thursday, July 7th. BTIG Research restated a “buy” rating and set a $230.00 target price on shares of Shire PLC in a research report on Tuesday, July 12th. Finally, Leerink Swann restated a “buy” rating and set a $213.00 target price on shares of Shire PLC in a research report on Tuesday, July 12th. Five investment analysts have rated the stock with a hold rating and twenty-two have given a buy rating to the company’s stock. Shire PLC presently has an average rating of “Buy” and a consensus target price of $228.15.
Shire PLC (NASDAQ:SHPG) opened at 187.70 on Friday. Shire PLC has a 52-week low of $147.60 and a 52-week high of $231.32. The stock has a 50 day moving average of $194.68 and a 200-day moving average of $187.77. The company has a market cap of $55.91 billion, a price-to-earnings ratio of 39.01 and a beta of 1.16.
Shire PLC (NASDAQ:SHPG) last posted its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $3.38 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $3.03 by $0.35. The company earned $2.43 million during the quarter, compared to analyst estimates of $2.28 billion. Shire PLC had a return on equity of 17.70% and a net margin of 13.19%. The company’s revenue for the quarter was up 55.9% compared to the same quarter last year. During the same period in the previous year, the company earned $2.63 EPS. On average, analysts forecast that Shire PLC will post $12.92 EPS for the current year.
The business also recently disclosed a dividend, which was paid on Friday, October 7th. Stockholders of record on Friday, September 9th were paid a dividend of $0.139 per share. The ex-dividend date of this dividend was Wednesday, September 7th. Shire PLC’s dividend payout ratio is currently 15.63%.
Several large investors have recently made changes to their positions in SHPG. Renaissance Technologies LLC boosted its stake in shares of Shire PLC by 12.6% in the first quarter. Renaissance Technologies LLC now owns 313,212 shares of the biopharmaceutical company’s stock worth $53,841,000 after buying an additional 35,100 shares in the last quarter. Reynolds Capital Management LLC bought a new stake in shares of Shire PLC during the first quarter worth about $206,000. OLD Mission Capital LLC bought a new stake in shares of Shire PLC during the first quarter worth about $28,179,000. Pictet Asset Management Ltd. boosted its stake in shares of Shire PLC by 18.6% in the first quarter. Pictet Asset Management Ltd. now owns 147,339 shares of the biopharmaceutical company’s stock worth $23,001,000 after buying an additional 23,105 shares in the last quarter. Finally, Quadrature Capital Ltd bought a new stake in shares of Shire PLC during the first quarter worth about $3,111,000. Institutional investors own 24.26% of the company’s stock.
Shire PLC Company Profile
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.